Intelligence · Drug directory

Pipeline & Investigational Drugs

Investigational and clinical-stage compounds without US or EU marketing approval — linked to ClinicalTrials.gov programs and congress coverage.

Quick answer

Pipeline & investigational drugs: NovaPharmaNews tracks 1,610 pharmaceutical drugs in this segment. Investigational and clinical-stage compounds without US or EU marketing approval — linked to ClinicalTrials.gov programs and congress coverage.

1,610 drugs · Pipeline · by data quality · Page 2 of 68

  1. arachis hypogaea extract

    ABYLQIS

    EMA: application withdrawn

    V01AA08
  2. arcitumomab

    CEA-SCAN

    EMA: withdrawn

    V09IA01
  3. arimoclomol

    MIPLYFFA

    EMA: application withdrawn

    N07
  4. ataluren

    TRANSLARNA

    EMA: unknown

    M09AX03
  5. autologous cartilage-derived articular chondrocytes, in-vitro expanded

    JELRIX

    EMA: application withdrawn

    M09AX02
  6. autologous glioma tumor cell lysates (inactivated)

    SITOIGANAP

    EMA: application withdrawn

    L01XX
  7. autologous human chondrocytes in vitro expanded

    ARTOBEND

    EMA: application withdrawn

    M09AX02
  8. autologous peripheral-blood mononuclear cells activated with prostatic acid phosphatase granulocyte-macrophage colony-stimulating factor (sipuleucel-t)

    PROVENGE

    EMA: withdrawn

    L03AX17
  9. avacincaptad pegol

    IZELVAY

    EMA: application withdrawn

    S01XA32
  10. bamlanivimab

    BAMLANIVIMAB AND ETESEVIMAB FOR COVID-19

    EMA: withdrawn from rolling review

  11. bardoxolone methyl

    IMBARKYD

    EMA: application withdrawn

  12. begelomab

    BEGEDINA

    EMA: application withdrawn

    L04AA35
  13. betibeglogene autotemcel

    ZYNTEGLO

    EMA: withdrawn

    B06A
  14. bifikafusp alfa

    NIDLEGY

    EMA: application withdrawn

    L01XY
  15. blarcamesine

    BLARCAMESINE ANAVEX

    EMA: application withdrawn

    N06D
  16. briakinumab

    OZESPA

    EMA: application withdrawn

    L04AC09
  17. camizestrant

    ETCAMAH

    EMA: unknown

    L02BA05
  18. carisbamate

    COMFYDE

    EMA: application withdrawn

  19. casirivimab

    RONAPREVE

    EMA: withdrawn

    J06BD07
  20. casopitant

    ZUNRISA

    EMA: application withdrawn

  21. cediranib maleate

    ZEMFIRZA

    EMA: application withdrawn

    L01XE32
  22. ceftobiprole

    ZEFTERA (PREVIOUSLY ZEVTERA)

    EMA: refused

    J01DI01
  23. characterised viable autologous cartilage cells expanded ex vivo expressing specific marker proteins

    CHONDROCELECT

    EMA: withdrawn

    M09AX02
  24. clostridium botulinum, serotype e, neurotoxin (150 kda)

    BOEY

    EMA: unknown

    M03AX01

Frequently asked questions

How many pipeline drugs are listed?

1,610 drug profiles match this regulatory segment in our published index.

Where does approval data come from?

Profiles combine FDA Drugs@FDA, EMA EPAR references, and regional authority feeds. See our data sources page for attribution.